BACKGROUND: Routine laboratory data may support CKD follow-up. We evaluated 12- and 24-month documented progression prediction and exploratory review outputs. METHODS: This retrospective single-center study used 2012-2025 hospital records. CKD required objective persistence for ≥90 days. Development used 2012-2021 indices; temporal evaluation used unseen patients indexed in 2022-2023. Among horizon-evaluable indices, the endpoint was documented sustained ≥40% estimated glomerular filtration rate (eGFR) decline or kidney failure. Development selected 12-month and conditional second-year models combined for non-decreasing cumulative risk. Laboratory and documentation outputs were assessed separately. RESULTS: Temporal evaluation of horizon-evaluable patients included 143 patients (10 event patients; 21/364 positive indices) at 12 months and 87 patients (22 event patients; 50/247 positive indices) at 24 months. Area under the precision-recall curve (AUPRC) was 0.510 (95% confidence interval [CI] 0.217-0.789) and 0.677 (0.459-0.853), respectively. Incremental 12-month AUPRC over age, sex and current eGFR was uncertain (difference -0.009, 95% CI -0.171 to 0.123). At 24 months, area under the receiver operating characteristic curve (AUROC) was higher than the core comparator (difference 0.057, 95% CI 0.007-0.121); clinical utility was not evaluated. Calibration slopes were 0.996 (0.689-1.640) and 1.028 (0.676-1.661); wide CIs precluded reliable individual-risk calibration. Documentation ranking did not improve on prior-mention strategies. CONCLUSIONS: This study is proof of concept. Small event counts, follow-up selection and uncertain incremental value limit interpretation. Multisite validation is required before implementation.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: